Dr Moira Cruickshank
Research Fellow
- About
-
- Email Address
- m.cruickshank@abdn.ac.uk
- Office Address
Health Services Research Unit
3rd Floor Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I joined the Knowledge Synthesis team of ACE following completion of my PhD in 2011. I have worked on a wide range of technology assessment appraisals and health technology assessment reviews.
Qualifications
- PhD Health Psychology2011 - University of Aberdeen
- Publications
-
Page 2 of 6 Results 11 to 20 of 56
The effects and safety of testosterone replacement therapy for men with hypogonadism: The TestES evidence synthesis and economic evaluation
Health Technology Assessment, vol. 28, no. 43Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.3310/JRYT3981
- [OPEN ACCESS] https://aura.abdn.ac.uk/bitstreams/6848212e-6da3-4654-8ab5-bdb67252f855/download
- [ONLINE] View publication in Scopus
Fruquintinib for previously treated metastatic colorectal cancer [ID6274]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned ReportsWhat is the impact of long-term COVID-19 on workers in healthcare settings? A rapid systematic review of current evidence
PloS ONE, vol. 19, no. 3 , e0299743Contributions to Journals: Review articlesCost-effectiveness of testosterone treatment utilising individual patient data from randomised controlled trials in men with low testosterone levels
Andrology, vol. 12, no. 3, pp. 477-486Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1111/andr.13597
- [OPEN ACCESS] https://aura.abdn.ac.uk/bitstreams/4998c88d-7fcf-4594-b082-8eb2eb688d19/download
- [ONLINE] View publication in Scopus
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
National Institute for Health and Care Excellence (NICE). 20 pagesBooks and Reports: Commissioned Reports- [ONLINE] https://www.nice.org.uk/guidance/ta948
- [ONLINE] Page 214-316
- [ONLINE] https://www.nice.org.uk/guidance/ta948/evidence
Netarsudil-latanoprost for previously treated openangle glaucoma or ocular hypertension [ID1363]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned ReportsClinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo:: Results Of Individual Patient And Aggregate Data Meta-analyses
Annual Meeting of the Endocrine Society 2023, bvad114.1704Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1210/jendso/bvad114.1704
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
The Lancet Healthy Longevity, vol. 4, no. 10, pp. e561-e572Contributions to Journals: ArticlesDeucravacitinib for treating moderate-to-severe plaque psoriasis
Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. 155 pagesBooks and Reports: Commissioned ReportsSecukinumab for Moderate-to-Severe Hidradenitis Suppurativa [ID4039]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned Reports